Key result
Second-generation valves linked to ~75% lower 1-year CV mortality vs. first-generation in ViV-TAVI.
Why the study?
Transcatheter aortic valve-in-valve implantation (ViV-TAVI) has emerged as an alternative to redo surgery for failed surgical aortic bioprostheses, motivating an evaluation of its safety and efficacy in Polish patients after surgical aortic valve replacement.
Observational (n=130)
Yes
Answers are grounded in this paper and cite their sources.
Supports second-generation valves in ViV-TAVI; leaves open need for randomized confirmation before practice change.
INTRODUCTION: Transcatheter aortic valve‑in ‑valve implantation (ViV‑TAVI) has emerged as an alternative to redo surgery in patients with failed surgical aortic bioprosthesis. OBJECTIVES: We evaluated the safety and efficacy of ViV‑TAVI in Polish patients after surgical aortic valve replacement. PATIENTS AND METHODS: This was a nationwide multicenter registry of ViV‑TAVI procedures. Data were collected using an online form, and the clinical follow ‑up lasted 1 year. RESULTS: From 2008 to 2020, 130 ViV‑TAVI procedures were performed (1.9% of all transcatheter aortic valve implantation [TAVI] cases). A considerable increase in ViV‑TAVI procedures since 2018 has been observed (n = 59, 45% of ViV‑TAVI cases). Hancock II, Freestyle, and homograft were the most frequently treated bioprostheses. The self ‑expanding supra ‑annular Corevalve / Evolut valve was used in 76% of cases. In 21% of cases, the mean postprocedural pressure gradient (PG) exceeded 20 mm Hg. All‑cause mortal‑ity at 1 year was 10.8%. Aortic valve stenosis was associated with a higher mean PG than aortic valve regurgitation or mixed disease (P = 0.004). Supra ‑annular transcatheter aortic valves were associated with lower mean PGs than intra ‑annular valves (P = 0.004). Second ‑generation devices were associated with shorter procedure time (120 min vs 135 min, P = 0.04), less frequent need for additional TAVI (2% vs 10%, P = 0.04), and lower 1‑year cardiovascular mortality (95% vs 82.8%, P = 0.03) than first‑generation valves. CONCLUSIONS: Transcatheter treatment of failed bioprostheses is increasingly common, with the best hemodynamic effect shown for supra ‑annular valves. The introduction of second‑generation valves has improved procedural and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Huczek et al. (2021) conducted an observational in Failed surgical aortic bioprostheses (n=130). Second-generation transcatheter aortic valve-in-valve implantation (ViV-TAVI) vs. First-generation transcatheter aortic valve-in-valve implantation was evaluated on 1-year cardiovascular survival (mortality) (HR 0.25, 95% CI 0.17-0.88, p=0.03). Second-generation transcatheter aortic valves improved 1-year cardiovascular survival compared to first-generation valves in ViV-TAVI, with 10.8% overall mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: